Clinical Trial Update: StrataCTX® as a Steroid Sparing Device [NA]

View source ↗

Summary

This clinical trial update reports that StrataCTX is being studied as a steroid-sparing device for cutaneous T-cell lymphoma and that the trial is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• StrataCTX

Snippet

Sponsor: Columbia University | Conditions: CTCL | NA | Status: RECRUITING